Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Introduction: Fatty liver is associated with metabolic syndrome (MetS) but it may also occur without MetS. Whether resolution of fatty liver in the general population affects risk of MetS is unknown. Our aim was to determine whether a change in fatty liver status (either the development of new fatty liver or the resolution of existing fatty liver) would modify the risk of de novo MetS. Methods: Two thousand eighty-nine people without hypertension, diabetes, and MetS were examined at baseline and at 5-year follow-up using a retrospective cohort study design. Fatty liver status was assessed at baseline and at follow-up by ultrasonography. Adjusted hazard ratios (aHR) and 95 % confidence intervals (CIs) for de novo MetS at follow-up were calculated controlling for the potential confounders, compared to the reference group (people who never had fatty liver at baseline and follow-up). Results: During follow-up, fatty liver developed in 251 people and fatty liver resolved in 112 people. After the adjustment for multiple confounders, persisting fatty liver and incident fatty liver development were associated with de novo MetS, with aHR of 2.60 (95 % CIs [1.61,4.20]) and 3.31 (95 % CIs [1.99,5.51]), respectively. Risk of new MetS in resolved fatty liver group was attenuated with insignificant aHR of 1.29 accompanying 95 % CIs of 0.60 and 2.80. Discussion: Development or maintenance of fatty liver is positively associated with occurrence of new MetS. Resolution of fatty liver status has similar risk of de novo MetS with those who never had fatty liver. Therefore, cautious management is needed with those with fatty liver.
Abstract
Introduction: Fatty liver is associated with metabolic syndrome (MetS) but it may also occur without MetS. Whether resolution of fatty liver in the general population affects risk of MetS is unknown. Our aim was to determine whether a change in fatty liver status (either the development of new fatty liver or the resolution of existing fatty liver) would modify the risk of de novo MetS. Methods: Two thousand eighty-nine people without hypertension, diabetes, and MetS were examined at baseline and at 5-year follow-up using a retrospective cohort study design. Fatty liver status was assessed at baseline and at follow-up by ultrasonography. Adjusted hazard ratios (aHR) and 95 % confidence intervals (CIs) for de novo MetS at follow-up were calculated controlling for the potential confounders, compared to the reference group (people who never had fatty liver at baseline and follow-up). Results: During follow-up, fatty liver developed in 251 people and fatty liver resolved in 112 people. After the adjustment for multiple confounders, persisting fatty liver and incident fatty liver development were associated with de novo MetS, with aHR of 2.60 (95 % CIs [1.61,4.20]) and 3.31 (95 % CIs [1.99,5.51]), respectively. Risk of new MetS in resolved fatty liver group was attenuated with insignificant aHR of 1.29 accompanying 95 % CIs of 0.60 and 2.80. Discussion: Development or maintenance of fatty liver is positively associated with occurrence of new MetS. Resolution of fatty liver status has similar risk of de novo MetS with those who never had fatty liver. Therefore, cautious management is needed with those with fatty liver.
참고문헌 (29)
- Yki-Jarvinen H., "Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome", Lancet Diabetes Endocrinol, 2, pp.901~910 (2014)
- Clark JM., "Hepatic steatosis and type 2 diabetes mellitus", Curr Diab Rep, 2, pp.210~215 (2002)
- Bedogni G., "Prevalence of and risk factors for nonalcoholic fatty liver disease : the Dionysos nutrition and liver study", Hepatology, 42, pp.44~52 (2005)
- Browning JD., "Prevalence of hepatic steatosis in an urban population in the United States : impact of ethnicity", Hepatology, 40, pp.1387~1395 (2004)
- Vernon G., "Systematic review : the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults", Aliment Pharmacol Ther, 34, pp.274~285 (2011)
- Flegal KM., "Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010", JAMA, 307, pp.491~497 (2012)
- Pan JJ., "Gender and racial differences in nonalcoholic fatty liver disease", World J Hepatol, 6, pp.274~283 (2014)
- Machado M., "Hepatic histology in obese patients undergoing bariatric surgery", J Hepatol, 45, pp.600~606 (2006)
- 지선하, "Linkage of Epidemiologic Evidence With the Clinical Aspects of Metabolic Syndrome", Korean Circulation Journal, 42(6), pp.371~378 (2012), 대한심장학회[DOI]
- Eckel RH., "The metabolic syndrome", Lancet, 365, pp.1415~1428 (2005)
- Ryoo JH., "The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men : 5-year’s prospective cohort study", Atherosclerosis, 227, pp.398~403 (2013)
- Lallukka S., "Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3", Diabetologia, 56, pp.886~892 (2013)
- Sung KC., "The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects", Atherosclerosis, 203, pp.581~586 (2009)
- Sung KC., "Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension", J Hepatol, 60, pp.1040~1045 (2014)
- Sung KC., "Resolution of fatty liver and risk of incident diabetes", J Clin Endocrinol Metab, 98, pp.3637~3643 (2013)
- Saadeh S., "The utility of radiological imaging in nonalcoholic fatty liver disease", Gastroenterology, 123, pp.745~750 (2002)
- Kassi E., "Metabolic syndrome : definitions and controversies", BMC Medicine, 9, pp.48~ (2011)
- Monetti M., "Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver", Cell Metab, 6, pp.69~78 (2007)
- Sung KC., "Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes", J Clin Endocrinol Metab, 96, pp.1093~1097 (2011)
- Kantartzis K., "The impact of liver fat vs visceral fat in determining categories of prediabetes", Diabetologia, 53, pp.882~889 (2010)
- Festa A., "Insulin resistance atherosclerosis S. elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes : the insulin resistance atherosclerosis study", Diabetes, 51, pp.1131~1137 (2002)
- Ardigo D., "The increase in plasma PAI-1 associated with insulin resistance may be mediated by the presence of hepatic steatosis", Atherosclerosis, 208, pp.240~245 (2010)
- Targher G., "Clinical review : nonalcoholic fatty liver disease : a novel cardiometabolic risk factor for type 2 diabetes and its complications", J Clin Endocrinol Metab, 98, pp.483~495 (2013)
- Gao Z., "Sirtuin 1(SIRT1)protein degradation in response to persistent c-Jun N-terminal kinase 1(JNK1)activation contributes to hepatic steatosis in obesity", J Biol Chem, 286, pp.22227~22234 (2011)
- Samuel VT., "Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease", J Biol Chem, 279, pp.32345~32353 (2004)
- Ix JH., "Mechanisms linking obesity, chronic kidney disease, and fatty liver disease : the roles of fetuin-A, adiponectin, and AMPK", J Am Soc Nephrol, 21, pp.406~412 (2010)
- Schwenger KJ., "Clinical approaches to non-alcoholic fatty liver disease", World J Gastroenterol, 20, pp.1712~1723 (2014)
- Targher G., "Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease : is there a link?", J Hepatol, 54, pp.1020~1029 (2011)
- Kim CW., "Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses", J Hepatol, 59, pp.351~357 (2013)